Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cilastatin Sodium

FDA-approved product (powder, intravenous).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Cilastatin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Endocarditis
  • Infection
  • Pneumonia
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

Cilastatin Sodium reaches ≥40% AI-predicted activity against M. tuberculosis, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cilastatin Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cilastatin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • To Compare Safety and Efficacy of Doripenem Versus Imipenem-Cilastatin in Patients With Ventilator-Associated Pneumonia

    NCT00589693 · start 2008-04

    Registered record
    Registry ID
    NCT00589693
    Conditions
    Ventilator-Associated Pneumonia
    Interventions
    Doripenem; Imipenem-Cilastatin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2008-04
    Completion
    2011-06
    Enrolment
    274

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator-Associated Pneumonia
    InterventionDoripenem; Imipenem-Cilastatin; Placebo
    PhasePhase 3
    Registry statusTerminated

  • A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

    NCT00445094 · start 2006-11

    Registered record
    Registry ID
    NCT00445094
    Conditions
    Infection; Pneumonia
    Interventions
    MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days; Comparator: amikacin / Duration of Treatment: 3 Days; Comparator: tazocin / Duration of Treatment: 3 Days; Comparator: vancomycin / Duration of Treatment: 3 Days
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-11
    Completion
    2007-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection; Pneumonia
    InterventionMK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days; Comparator: amikacin / Duration of Treatment: 3 Days; Comparator: tazocin / Duration of Treatment: 3 Days; Comparator: vancomycin / Duration of Treatment: 3 Days
    PhasePhase 4
    Registry statusCompleted

  • Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections

    NCT00136201 · start 2005-11

    Registered record
    Registry ID
    NCT00136201
    Conditions
    Abdominal Abscess
    Interventions
    tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-11
    Completion
    2006-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAbdominal Abscess
    Interventiontigecycline
    PhasePhase 3
    Registry statusCompleted

  • Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects

    NCT00081744 · start 2002-11

    Registered record
    Registry ID
    NCT00081744
    Conditions
    Gram-Positive Bacterial Infections; Cross Infection
    Interventions
    Tigecycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-11
    Completion
    2004-08
    Enrolment
    850

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Positive Bacterial Infections; Cross Infection
    InterventionTigecycline
    PhasePhase 3
    Registry statusCompleted

  • Complicated Skin and Skin Structure Infections

    NCT00619710 · start 2001-02

    Registered record
    Registry ID
    NCT00619710
    Conditions
    Skin Infection; Abscess; Cellulitis
    Interventions
    Meropenem; Imipenem-cilastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-02
    Completion
    2004-04
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Infection; Abscess; Cellulitis
    InterventionMeropenem; Imipenem-cilastatin
    PhasePhase 3
    Registry statusCompleted